Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.

March 16, 2025
In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN). He emphasized that the company's innovative approach to drug development and strong fundamentals make it a solid investment choice.

Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of drugs. The company has a diversified portfolio of products targeting various therapeutic areas, including oncology, ophthalmology, and cardiovascular diseases.

Cramer highlighted the company's significant advancements in the development of novel treatments for chronic diseases, such as its groundbreaking monoclonal antibody therapy for asthma and atopic dermatitis. He lauded Regeneron's collaboration with other pharmaceutical giants, including Sanofi, which has further bolstered its pipeline of potential blockbuster drugs.

The financial expert also pointed out Regeneron's strong financial performance, with consistent revenue growth and solid profitability. He emphasized that the company's robust research and development pipeline indicates promising future prospects.

In conclusion, Cramer urged investors to consider adding Regeneron Pharmaceuticals Inc. to their portfolio, citing the company's innovative approach to drug development, strong partnerships, and promising financial outlook. To ensure a well-informed investment decision, he recommended seeking guidance from professionals at Stocks Prognosis, who specialize in predicting the movement of stocks, including REGN.

Find out how the REGENERON PHARMACEUTICALS, INC. rate is expected to change

Get Forecast for REGN

Investor opinions & comments:

I'm hesitant to invest in pharmaceutical companies because of the ethical concerns surrounding drug pricing. I'd need more information about Regeneron's practices and pricing policies before considering it as an investment
— from SavingsSarah at 03-19-2025 04:24
I'm skeptical of Cramer's recommendations. It seems like he's always touting different stocks and it's hard to know if he genuinely believes in them or if he's just trying to drive up prices. I'll do my own research before making any investment decisions
— from BudgetBrittany at 03-18-2025 20:02
Regeneron has been on my radar for a while and it's great to see them getting positive attention from experts like Cramer. I'll definitely be doing more research and considering adding REGN to my portfolio
— from StockSally at 03-18-2025 18:04
I'm not so sure about investing in biotech companies. The industry can be volatile and there's always the risk of FDA approval setbacks. I'd want to do more thorough research before making any investment decisions
— from InvestorIsabella at 03-18-2025 12:58
I'm a big fan of Cramer's insights and I trust his judgment. If he's recommending Regeneron, there must be something there. I'll definitely do some research and consider adding it to my investment portfolio
— from AlexPhillips at 03-18-2025 07:48
I've already invested in Regeneron and I'm happy to see Cramer endorsing it. It gives me confidence that I made a smart decision. It's always reassuring to have financial experts like him backing up your investment choices
— from FinanceFiona at 03-18-2025 06:21
I've heard good things about Regeneron's collaborations with other pharmaceutical companies. It seems like they have a strong pipeline and potential for future success. I'm definitely interested in learning more
— from AudreyRussell at 03-18-2025 06:08
I've been following Regeneron for a while and I'm impressed with their advancements in drug development. It's great to see industry experts like Cramer recognizing their potential. I'll definitely be considering REGN for my portfolio
— from CharlesGrant at 03-17-2025 20:01
Great news! I've been following Regeneron for a while now and it's exciting to see their innovative approach paying off. I'll definitely look into adding REGN to my portfolio
— from WilliamReed at 03-16-2025 09:47
If you want to leave a comment, then you need Login or Register





Other news for REGN

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....



Related news

REGNMarch 15, 2025Regeneron Pharmaceuticals Inc.: A Promising Investment Opportunity  ~2 min.

Regeneron Pharmaceuticals Inc....

REGNJanuary 10, 2025Regeneron Pharmaceuticals Inc. Poised for Strong Growth in Q4 and Full Year 2024  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has recently announced that it will be releasing its fourth quarter and full year 2024 earnings on February 4, 2025....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....

REGNJanuary 31, 2025Regeneron Pharmaceuticals Inc.: A Rising Star in the Biotech Industry  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the biotech industry with its innovative drug development and collaboration efforts....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: A Promising Future Ahead  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, with investors enjoying a decent 89% return over the past five years....